STOCK BASED COMPENSATION (Details Narrative) - USD ($)				3 Months Ended
	Mar. 25, 2022	Mar. 23, 2022	Jan. 12, 2022	Mar. 31, 2022	Mar. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Compensation costs				$ 1,200,000	$ 750,000
Number of restricted stock award, value				0	0
Common stock issued through stock options				$ 993,000	$ 2,588,000
Options outstanding				3,700,000
Aggregate intrinsic value				$ 32,100,000
Number of shares available for grant				2,300,000
Five Employees [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of restricted stock award			25,000
Number of restricted stock award, value			$ 613,000
Grants vest term			5 years
Nine Members of Board of Directors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of common stock award		5,598	5,508
Fair value of grant options		$ 135,000	$ 135,000
Two Employees [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of restricted stock award	78,000
Number of restricted stock award, value	$ 1,900,000
Grants vest term	5 years
Forty-Five Participants [Member] | Stock Options [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Grants vest term	5 years
Fair value of grant options	$ 2,100,000
Option to purchase common stock	470,800
Eight Participants [Member] | Stock Options [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common stock issued through stock options, shares				78,160
Weighted-average exercise price				$ 12.70
Common stock issued through stock options				$ 993,000
Aggregate intrinsic value of options exercised				$ 955,000